Preclinical cutaneous topical wound treatment with hypoxia- preconditioned autologous blood

• Applicant: Dr. Philipp Moog
• Subject Area: Orthopaedics, Traumatology, Reconstructive Surgery
• Term: since 2022
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 508466325

In the last decade there has been a growing interest in using regenerative therapies based on autologous blood. With the extracorporeal wound simulation (EWS) of autologous peripheral blood cells, the physiological growth factor secretomes and signaling pathways are mimicked and obtained extracorporeally. These patient-specific hypoxia-preconditioned secretomes (HPS) optimize the angiogenic and lymphangiogenic growth factor profile in vitro and achieve a significant improvement over currently available blood-based secretomes such as platelet rich plasma (PRP). The angiogenic effectiveness of these cell-free secretomes is not restricted by diabetes mellitus or by oral anticoagulation in vitro. The EWS-based therapies can can be applied by topical bioactive wound dressings. In one not previously published study, a dose-effect difference was seen with either 10% or 40% HPS in the in vivo mouse model. 40% HPS favored a faster wound closure than 10% HPS. Compared to the control, both HPS dosage induced faster wound closure. The next logical step on the way to clinical application is the testing in the preclinical established porcine wound model. The goals we are trying to archieve: 1.) To test the effectiveness in a preclinical model, which corresponds as closely as possible to the circumstances in humans. The effectiveness shown in the mouse model is to be confirmed with the porcine in vivo model. We can include the testing of the autologous application, since the blood volume is sufficient for this in the large animal model; 2.) to analyze the cellular mechanisms, precisely timed and appropriate to the stage. The growth factor mixtures obtained through our process could be used in other areas, such as 1) tissue engineering, 2) to increase the transplant volume (e.g. in lipofilling) or 3) to improve the healing of transplants in damaged tissues (e.g. irradiated tissue ; chronic / ischemic wounds).

• DFG Programme: Research Grants
• Co-Investigators: Dr. Jun Jiang; Dr. Haydar Kükrek; Professor Dr. Hans-Günther Machens